Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Intrinsic Value
Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. [ Read More ]
The intrinsic value of one
Jiangsu Hengrui Pharmaceuticals Co Ltd
stock under the Base Case scenario is
23.63
CNY.
Compared to the current market price of 41.86 CNY,
Jiangsu Hengrui Pharmaceuticals Co Ltd
is
Overvalued by 44%.
Jiangsu Hengrui Pharmaceuticals Co Ltd's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
Jiangsu Hengrui Pharmaceuticals Co Ltd or that its price is influenced by factors unrelated to fundamentals.
Jiangsu Hengrui Pharmaceuticals Co Ltd's market capitalization is 266.2B CNY.
Jiangsu Hengrui Pharmaceuticals Co Ltd stock price is 41.86 CNY.
Jiangsu Hengrui Pharmaceuticals Co Ltd stock (23.63 CNY) is 44% less than its price (41.86 CNY).
Jiangsu Hengrui Pharmaceuticals Co Ltd stock (19.38 CNY) is 54% less than its price (41.86 CNY). Open DCF Valuation
Jiangsu Hengrui Pharmaceuticals Co Ltd stock (27.88 CNY) is 33% less than its price (41.86 CNY). Open Relative Valuation
Jiangsu Hengrui Pharmaceuticals Co Ltd has upside potential of 38% compared to the average analyst price target.
Open Wall St Estimates
Jiangsu Hengrui Pharmaceuticals Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue has grown by 3% over the past 12 months.
Jiangsu Hengrui Pharmaceuticals Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 16%.
Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue has been falling by 5% per year for the last 3 years.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive Operating Income for the last twelve months.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
Jiangsu Hengrui Pharmaceuticals Co Ltd's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive Net Income for the last twelve months.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive Free Cash Flow for the last twelve months.
Jiangsu Hengrui Pharmaceuticals Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 22% to 11%.
Jiangsu Hengrui Pharmaceuticals Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 39% to 16%.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive three-year average ROIC (Return on Invested Capital): 25%. The company is efficient at using invested capital to generate operating income.
Jiangsu Hengrui Pharmaceuticals Co Ltd has positive Gross Profit for the last twelve months.
Jiangsu Hengrui Pharmaceuticals Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.01.
Jiangsu Hengrui Pharmaceuticals Co Ltd's short-term assets (30B CNY) exceed its short-term liabilties (2B CNY).
Jiangsu Hengrui Pharmaceuticals Co Ltd's long-term assets (42B CNY) exceed its long-term liabilties (3B CNY).
Jiangsu Hengrui Pharmaceuticals Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (17B CNY) than debt (396m CNY).
Jiangsu Hengrui Pharmaceuticals Co Ltd's Altman Z-Score is very high and is equal to 57.43.
Valuation Backtest
Jiangsu Hengrui Pharmaceuticals Co Ltd
Run backtest to discover the historical profit from buying and selling
Jiangsu Hengrui Pharmaceuticals Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Jiangsu Hengrui Pharmaceuticals Co Ltd
Balance Sheet Decomposition
Jiangsu Hengrui Pharmaceuticals Co Ltd
| Current Assets | 29.9B |
| Cash & Short-Term Investments | 17B |
| Receivables | 8.7B |
| Other Current Assets | 4.2B |
| Non-Current Assets | 12.1B |
| Long-Term Investments | 1.5B |
| PP&E | 7B |
| Intangibles | 2.9B |
| Other Non-Current Assets | 679.1m |
| Current Liabilities | 2.3B |
| Accounts Payable | 1.3B |
| Accrued Liabilities | 225.3m |
| Short-Term Debt | 319.1m |
| Other Current Liabilities | 409.6m |
| Non-Current Liabilities | 840.8m |
| Long-Term Debt | 76.9m |
| Other Non-Current Liabilities | 763.9m |
Earnings Waterfall
Jiangsu Hengrui Pharmaceuticals Co Ltd
|
Revenue
|
22.3B
CNY
|
|
Cost of Revenue
|
-3.7B
CNY
|
|
Gross Profit
|
18.7B
CNY
|
|
Operating Expenses
|
-15B
CNY
|
|
Operating Income
|
3.6B
CNY
|
|
Other Expenses
|
597.1m
CNY
|
|
Net Income
|
4.2B
CNY
|
Free Cash Flow Analysis
Jiangsu Hengrui Pharmaceuticals Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Jiangsu Hengrui Pharmaceuticals Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Jiangsu Hengrui Pharmaceuticals Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Jiangsu Hengrui Pharmaceuticals Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Jiangsu Hengrui Pharmaceuticals Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Jiangsu Hengrui Pharmaceuticals Co Ltd
According to Wall Street analysts, the average 1-year price target for
Jiangsu Hengrui Pharmaceuticals Co Ltd
is 57.66 CNY
with a low forecast of 42.62 CNY and a high forecast of 121.8 CNY.
Shareholder Return
Price
Jiangsu Hengrui Pharmaceuticals Co Ltd
| Average Annual Return | 5.82% |
| Standard Deviation of Annual Returns | 47.65% |
| Max Drawdown | -71% |
| Market Capitalization | 266.2B CNY |
| Shares Outstanding | 6 379 002 274 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jiangsu Hengrui Pharmaceuticals Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. The company is headquartered in Lianyungang, Jiangsu and currently employs 24,491 full-time employees. The company went IPO on 2000-10-18. The firm's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Jiangsu Hengrui Pharmaceuticals Co Ltd
stock under the Base Case scenario is
23.63
CNY.
Compared to the current market price of 41.86 CNY,
Jiangsu Hengrui Pharmaceuticals Co Ltd
is
Overvalued by 44%.
You don't have any saved screeners yet
